Objective: To analyze temporal patterns of antiretroviral (ARV) prescribing practices relative to nationally defined guidelines in treatment-naive patients with HIV-1 infection.
vidence-based treatment guidelines are increasingly used to guide clinicians' medical care decisions in a variety of chronic diseases. 1 Expert panels, independent or convened by government agencies, develop and revise evidence-based guidelines. Evaluations of the quality of health care delivered and reimbursement decisions by payers are increasingly related to providers' adherence to published guidelines.
Rapid development of successful antiretroviral (ARV) therapies has dramatically changed the treatment of HIV infection. After 1996, when the use of combination ARV medications became standard, HIV infection was transformed from a rapidly progressive and nearly uniformly fatal condition to a treatable chronic infection. 2 The complexity of ARV treatment has reduced ARV adherence and increased drugdrug interactions and metabolic toxicities, however. Although many ARV combinations are widely recognized as standard treatment, other ARV combinations are discouraged because of excess toxicities, regimen complexity, or adverse drug interactions. 2 HIV expert panels have developed guidelines for initiation and appropriate use of ARVs in HIV-1 infection to account for this complexity of ARV management. [2] [3] [4] [5] The influence of the HIV treatment guidelines on clinical practice and outcomes is potentially important but understudied. In particular, better understanding of treatment patterns contemporary with guidelines might show that evolving guidelines lead to changes in practice patterns or that guideline recommendations actually lag behind usage patterns. Several researchers have described ARV utilization patterns but have not specifically studied rates of adherence to HIV treatment guidelines. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] We examined the relation between evolving treatment guidelines and initial ARV regimen choices.
METHODS

Reference Cohort
ARV data were analyzed using the US Department of Veterans Affairs (VA) immunologic case registry (ICR), which contains demographic and clinical data from VA clinical records. [18] [19] [20] [21] [22] Patients who received at least 1 annual service contact between January 1992 and December 2004 were included. ARV treatment-naive patients were defined as subjects who had not received an ARV prescription from the VA and whose date of first ARV prescription was at least 1 month after ICR entry. We excluded patients who had an HIV-1 viral load ,500 copies/mL at any point 3 months before their first recorded treatment.
Patients were classified by age (based on their age on January 1 of the relevant year: 18-30, 31-40, 41-50, 51-60, 61-70, and $71 years). Patients were assigned to 1 of 6 predesignated VA race/ethnicity groups: non-Hispanic white, Hispanic, black, Pacific Islander/Asian, American Indian/Alaskan native, and other (patients with missing race/ethnicity information). Finally, patients were classified into 1 of 4 geographic regions in the United States (East, South, Midwest, and West) according to first ICR entry.
Antiretroviral Classifications
ARV medications were grouped into 3 classes: (1) nucleoside reverse transcriptase inhibitor (NRTI), (2) non nucleoside reverse transcriptase inhibitor (NNRTI), and (3) protease inhibitor (PI). ARV regimens were defined as (1) monotherapy, or treatment with a single NRTI, NNRTI, or PI; (2) combination NRTI therapy, consisting of 2 or more NRTIs used together with no other class of ARV; and (3) dual-class therapy, consisting of at least 2 NRTIs in conjunction with at least 1 PI or 1 NNRTI. Ritonavir (RTV) prescribed at $400 mg/d was considered an additional ARV agent.
Statistical Analyses
We compared patterns of ARV use in the VA with recommendations from published statements of National Institutes of Health (NIH) consensus conferences (1990 and 1993) 23, 24 and from the International AIDS Society-USA (IAS-USA) Panel (1996 and . 25, 26 In 1998, the VA formally adopted the US Department of Health and Human Services (DHHS) guidelines, after which we compared patterns of ARV use in the VA with these guidelines. We computed the number of patients initiating ARV regimens according to categories specified in the guidelines: (1) ''preferred,'' (2) ''alternative,'' (3) ''generally not recommended,'' and (4) ''not recommended.'' We created a fifth category, ''other,'' for regimens that did not fall into 1 of the 4 guideline-specified categories. For not-recommended regimens, we distinguished between those having overlapping toxicity and those having modest antiviral activity. For ''other'' regimens, we computed the frequency of different ARV components as well as the number and proportion of patients according to the number of agents in the regimen (1, 2, 3, or $4). We further calculated the number of agents in regimens, independent of the guideline classification.
Logistic regression was used (variables included age group, gender, race/ethnicity, US region, clinic size, academic affiliation, CD4 cell count, HIV-1 viral load within the 3 months preceding initiating therapy, and duration of care in VA) to determine why patients received a preferred or alternative regimen compared with ''other'' regimen as initial therapy. We carried out similar analyses using 3 versus 4 (or more) agents in combination as the dependent variable regardless of guideline status. Univariate and multivariate odds ratios (ORs) were calculated using the Intercooled STATA 8.0 for Windows 98/95 NT statistical software package (Stata Corporation, College Station, TX). Table 1 lists US guidelines on ARV treatment for HIV-1-infected ARV-naive adults. Initial NIH recommendations in 1990 and 1993 advocated use of zidovudine (ZDV) or didanosine (ddI) for patients with CD4 counts ,500 cells/mL. 23, 24 In 1996 and 1997, IAS-USA Panel guidelines recommended combination NRTI and dual-class therapy, respectively. 25, 26 In 1998, the DHHS established a new format that contained 25 preferred, 10 alternative, and 4 notrecommended regimens. 
RESULTS
Guideline Development
Reference Cohort
During the study period, 57,210 unique patients were entered into the ICR. Patients were excluded if they were missing values for gender, date of first ICR data entry, or age (N = 397). Further excluded were patients older than 99 years or younger than 19 years (N = 19) and those whose date of AIDS diagnosis was recorded as before 1985 
Demographics and Clinical Outcomes
The number of unique treatment-naive patients was 1558 in 1992, increasing to a high of 2310 in 1996 and steadily declining to 651 through December 2004. More than 97% of patients were men. In 1992, 14% of treatmentnaive patients were 51 years of age or older compared with 31% of patients in 2004. Individuals identified as white declined progressively from 1992 through 2004, whereas those identified as black and other increased. Finally, the number of patients receiving care in the South increased, whereas the number of patients receiving care in the East decreased. NNRTI-and PI-based regimens FTC an option for part of a preferred or alternative 2-NRTI backbone ABC, indicates abacavir; d4T, stavudine; EFV, efavirenz; fosA, fosamprenavir; FTC, emtricitabine; IND, indinavir; LPV, lopinavir; TNF, tenofovil; /r, ritonavir-boosted; RTV, ritonavir; SQV-HGC, saquinavir-hard-gel capsule; 3TC, lamivudine; TDF, tenofovir.
*Addition of hydroxurea with any ARVs. †Includes 2 general classes of not recommended ARV regimens: toxicity based (ZDV/d4T, ddC/ddI, ddC/3TC, ddC/d4T) and those with modest activity (all monotherapies). ‡In 2003, 2 agent ARV combinations were classified as having modest activity and therefore not recommended.
Initial Combination Regimens and Guideline Recommendations
In 1992, 1255 patients (81.2%) initiated ZDV monotherapy, the preferred single-agent NRTI regimen at the time, whereas the remaining 290 patients (18.8%) received ddI or zalcitabine (ddC) monotherapy or a 2-agent NRTI regimen ( Table 2 ). The proportion of patients receiving 2-agent combinations increased from 4.4% in 1992 to 53.6% in 1996.
The use of single-agent NRTI regimens for treatment initiation decreased to 2.3% of all initial ARV regimens prescribed in 1997 and has remained at ,2%. The use of 2-agent NRTI combinations peaked in 1996, which is the only year that guidelines listed this combination as a preferred regimen. Approximately 80% of 2-agent combinations used in 1996 were from the preferred list.
Dual-class regimens consisting primarily of 3 or 4 agents were prescribed to 26% of patients in 1996, increasing to 64% in 1997. By 1999, the proportion receiving 3-or 4-agent combinations exceeded 94%. From 1997 onward, no more than 72% of patients initiated preferred or alternative dual-class regimens. Alternative regimens were used at a consistently lower rate than preferred regimens and were used in ,1% of patients between 2000 and 2002. From 1998 onward, the use of ''other'' regimens not on the preferred or alternative list has ranged from 21% to 56%, with 15% to 24% of patients receiving 4 (or more) agents as an ''other'' initial regimen.
PI-based regimens have been recommended since 1997, although they were a frequently used alternative option in 1996 (N = 354). The percentage of patients receiving a preferred PI-based regimen has declined steadily since 1997 and was equivalent to 6.5% in 2004. NNRTI-based regimens were added to the preferred list in 1999 and have remained stable at between 29% and 36% since 2000.
Because the categories of not recommended and generally not recommended regimens were introduced in 1998, the use of these regimens has been consistently low (see Table 2 ). Before this, use of regimens that were subsequently recommended to be virologically undesirable or had overlapping toxicities varied between 8.3% (1993 and 1994) and 13% (1996) . After 1998, no one received any of these combinations. The proportion of patients receiving regimens with modest activity has generally been ,1% to 3%.
Use of 3-Agent ''Other'' Combinations Table 3 summarizes Table 4 shows the odds of using preferred or alternative combinations, compared with ''other'' combinations from 1996 through 2004. In univariate analyses, patients were significantly more likely to receive a preferred or alternative regimen if they were 61 to 70 years of age, were black, received care other than in the western US, had CD4 counts between 201 and 350 cells/mL (or data not recorded or not available), had an HIV-1 viral load between 20 and 50,000 copies/mL (or missing), or started treatment before 1999 (except for 1997). Adjustment for all factors simultaneously in multivariate logistic regression analysis revealed that factors associated with greater odds of receiving a preferred or alternative regimen still included being 61 to 70 years of age, being black, receiving care other than in the western US, having CD4 counts between 201 and 350 cells/mL (or data not recorded or not available), having an HIV-1 viral load between 20 and 50,000 copies/mL (or missing), or starting treatment before 1999 (except for 1997). A greater odds of receiving ''other'' regimens included clinic size .50 patients and receiving care in the western US.
Factors Associated With Use of 3-Agent Versus 4 (or more)-Agent Combinations
Age, gender, clinic size, and academic affiliation were not associated with greater use of 3-agent regimens (see Table  4 ). The odds of receiving 3 versus 4 or more agents were significantly greater in blacks, those starting treatment before 1999, and those with .7 months of follow-up preceding treatment. The odds of receiving 4 or more agents were higher in the western US, in those with CD4 counts ,200 cells/mL, and in those with viral loads .50,000 copies/mL (univariate only). Figure 1 displays the frequency of ARV regimen initiation relative to the timing of guideline recommendation announcements. In almost all cases, clinical practice patterns anticipated guideline recommendations by 6 to 12 months, particularly for regimens that were initially listed as preferred or alternative and later listed as alternative or not recommended (ie, monotherapies, unboosted PIs). Despite being listed as not generally recommended (for too little data available), tenofovir use increased significantly 15 months before being listed on the preferred list. For ARVs that were only listed as preferred, clinical utilization anticipated the guidelines for lopinavir and was simultaneously adopted for efavirenz-containing regimens.
Treatment Initiation Patterns Relative to Guideline Updates
DISCUSSION
Professional group-derived treatment guidelines have been important vehicles for communication of scientific advancements, limitations, risks, and proper use of new therapies. Our study is the first comparing ARV utilization patterns with contemporary guideline recommendations in HIV-infected treatment-naive patients. That insurance was not a barrier for ARV access was of particular importance. Therefore, we could explore other factors that may influence ARV prescribing patterns. The correlation between prescribing patterns and guidelines was greatest for recommendations that inform physicians what not to do so as to avoid harm rather for than recommendations that inform physicians what to do so as to improve efficacy. This difference could reflect a number of factors, including a large and rapidly changing number, complexity and scope of recommendations, lag in available new evidence and publication of guidelines, varying interpretation of evidence between guideline committees and treating physicians, and local and regional considerations (eg, patient mix) that may affect treatment patterns.
We found systematic differences in ARV treatment among blacks compared with nonblacks. A number of previous studies reveal disparities in HIV care related to race. [11] [12] [13] 15, 16, 27 Factors associated with non-HAART regimens in non-VA settings include active substance abuse, 7, 28 inconsistent clinical follow-up, 9 and lack of insurance. 11, 15 In the VA, blacks compared with nonblacks were more likely to receive preferred or alternative regimens and less likely to receive 4 (or more)-agent regimens, however. We know of no data (even in the guidelines) suggesting that blacks respond more or less effectively than nonblacks to 3-agent regimens. We also cannot ascertain the extent to which the choice was based on the regimen's convenience, tolerability, provider perceptions, or patient preferences. Recent provider survey data indicate that ARV treatment decision-making may be influenced by race or underlying HIV risk factors. 29 In addition, patient involvement in the treatment decision-making process is likely to influence initial choices as well. 30, 31 Patients receiving care in the western US were more likely to be prescribed ''other'' regimens and more than 3 agents in combination. Regional variation in clinical care has been a subject of intense study for decades. 32 Significant regional variation in clinical practice has been described for a variety of chronic diseases but has not been previously described in any detail for ARV use. 33 No consistent explanation can account for this phenomenon observed in the management of chronic non-HIV diseases. Although patient preferences and economic incentives (ie, payer mix, reimbursement rates, access to or limitations in care) may account for some of the variation, economic incentives are not an issue in the VA. Yet, the VA is subject to the same regional variation in chronic disease practice patterns even after accounting for risk adjustment. 34 Further analysis indicates that VA clinical practice mirrors local community practice and may simply reflect local provider opinions and patient preferences. Variation in ARV use is unlikely explained by differences in VA HIV provider experience or VA infrastructure differences compared with local community practice. Seventy-five percent of VA medical centers provide HIV care in subspecialty clinics, and the average VA HIV provider has more than 10 years of HIV clinical experience, having treated an average of 120 patients in the last 5 years. 35 Our findings highlight the need to understand the causes and implications of such variation better for the health of persons with HIV as well as the need to initiate targeted approaches to reduce unwarranted variation. Whether patients may have received ARV prescriptions from outside the VA that were not recorded in the ICR is important to our study's validity. A recent representative survey of 573 veterans found that ARVs were obtained by veterans (primarily treatment experienced) outside the VA at a rate of ,3.8%. 36 More than 80% of patients had greater than 2 months of follow-up in the ICR before ARV initiation. Extending follow-up to 3 months before treatment initiation did not change our findings (data not shown). Recent data from Gandhi and colleagues 37 indicate that 40% of HIV-positive veterans received care in the VA for an average of 3 years before their HIV diagnosis and entry into the ICR, emphasizing that a significant minority of veterans are already in care for years before diagnosis; therefore, ARV treatment initiation outside the VA would be unlikely. We cannot completely exclude the possibility that patients had prior ARV use and appeared in the ICR as ARV treatment naive. It is possible then, but unlikely, that ARV initiation choices in VA could have been affected or biased by ARV treatment history not recorded in the ICR.
A substantial number of the patients started treatment well below the CD4 cell count thresholds that were suggested by contemporary guidelines. Of those veterans initiating treatment between 1998 and 2000, when the guidelines suggested that treatment should be initiated when the CD4 count was ,500 cells/mL, on average, 60% had a CD4 count ,350 cells/mL and 40% had a CD4 count ,200 cells/mL when treatment was initiated. Between 2001 and 2004, when the guidelines suggested that treatment should be initiated when the CD4 count was ,200 cells/mL and should be offered when the CD4 count was ,350 cells/mL, on average, 25% had a CD4 count ,100 cells/mL and 15% had a CD4 count of ,50 cells/mL at the time of treatment initiation. Our findings support evidence that this is a consequence of delayed identification of HIV infection rather than lack of adherence to treatment guidelines. A recent VA study found that 55% of patients who were recently diagnosed with HIV infection had CD4 counts ,200 cells/mL. 37 This may correlate with key organizational, patient, or practitioner factors currently not recorded in the ICR such as hard-to-reach populations living in settings far from a VA facility 13 or comorbidities such as homelessness, mental illness, or substance abuse. As reported elsewhere, our data may help to identify strategies to narrow gaps related to disparities in care access, treatment, and outcome. 38, 39 The relatively high rate of ''other'' regimens suggests that research is warranted to assess how being assigned to different categories of ARV use-preferred, alternative, and 3-to 4-drug ''other'' combinations-is related to clinical outcomes. Some of the use of ''other'' combinations may be explained by revisions in guideline statements and preferred use of other agents, notably nevirapine, abacavir, and tenofovir. A recent study addressing this question in children initiating ARV treatment found that 22% were not placed on guideline-recommended regimens and that 15% were started on ''other'' ARV combinations. 40 After 1997, approximately 20% of initial ARV regimens contained 4 or more active agents and were more likely to be prescribed to patients with lower CD4 cell counts and higher viral loads. This suggests that practitioners were augmenting regimens with additional agents in patients who were at particularly high risk for HIV complications or that patients were deemed less likely to respond to a recommended 3-agent regimen. Reports from at least 1 other large cohort indicate that a small percentage of patients (5%) were started on ARV regimens of 4 or more agents, although the reasons for such decisions were not given. 41 Several small studies comparing treatment initiation with 3 versus 4 or more ARV drugs in ARV-naive patients suggest equivalent virologic outcomes. Nevertheless, there is a suggestion that more ARV drugs may accelerate the timing and percentage of those achieving an undetectable viral load. [42] [43] [44] Our study suggests that providers anticipated many guideline recommendations well before their publication. This may be explained, in part, by the lengthy process required for expert panel review or the fact that firm recommendations cannot be made until there are adequate data on potential efficacy or toxicities of specific regimens. Some guideline panel recommendations and updates are published in peer-reviewed journals, further lengthening the time to publication and availability to providers. The DHHS guidelines were originally published in 1998, however, with 1 update appearing in a peer review publication in 2002. 45, 46 DHHS updates have consistently been updated electronically and are therefore available to VA practitioners via the Internet when released. As guidelines became released more often than annually and by the DHHS, the time between mean uptake/decrease and official guideline recommendations has narrowed.
Our study also suggests that adherence to safety recommendation guidelines is closely followed and serves as an important benchmark. Conversely, lower practitioner use of ARV effectiveness guidelines (possibly because of the rapidly changing nature and complexity of suggestions) suggests that simplification of guidelines should be studied to increase potential adherence.
There are numerous examples of departure from clinical practice guidelines, 47 including examples in HIV primary care. For example, current US Public Health Service (USPHS) guidelines recommend tuberculin skin testing (TST) for all newly diagnosed HIV-infected patients. A recent study in US clinics found that just more than half of the newly diagnosed patients had received TST. Patient demographics had little effect on adherence to guidelines. Factors associated with higher TST guideline adherence included underlying risk factors for tuberculosis, increased clinic visits, use of other prophylactic medications for HIV care, and a written policy for TST in the clinic. 48 Whether HIV treatment decisions based on adherence or nonadherence to guideline recommendations result in significant clinical outcome differences requires study. Improved understanding of the relation of providers' prescribing behavior to ARV treatment guidelines may help to identify ways to improve development and timely communication of future treatment guidelines.
